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Identity 
Other names: MARKL1; KIAA1860 
HGNC (Hugo): MARK4 
Location: 19q13.2 
DNA/RNA 
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Description 
Spans 55,6 kb; 18 exons 
Transcription 
3,6 kb mRNA of MARK4S isoform, 3,22 kb of 
MARK4L isoform (alternative splicing-skipping of 
exon 16, which leads to a change in the reading frame). 
Protein 
Description 
688 amino acids (aa) for MARK4S isoform and 752 aa 
for MARK4L isoform; belongs to the MARK family of 
protein kinases and contains from aa 59 to 314 a 
Serine-Threonine kinase catalytic domain with two 
activating phosphorylation sites. A short sequence (T 
region) contains a putative membrane-targeting motif. 
This region is followed by a ubiquitin-associated 
(UBA) domain. The spacer is the least-conserved 
region among MARKs proteins. This region is 
followed by a strikingly conserved C-terminal domain. 
In MARK4 the C-terminal domain differs between 
MARK4S and MARK4L isoforms. 
Expression 
The MARK4S isoform is predominantly expressed in 
the brain and at low levels in the heart. The MARK4L 
isoform is expressed ubiquitously in all tissues, with a 
highly abundant expression in testis, neural progenitors 
and glial tumors. MARK4L is downregulated during 
glial differentiation. 
Localisation 
Protein was detected homogeneously in cytoplasm. 
Function 
MARK4 is considered to play a role as a messenger of 
the Wnt-signaling pathway. MARK4L represents a 
mitogenic-associated isoform. 
Homology 
MARK1, MARK2 (Emk1), MARK3 (p78/C-TAK1), 
par1, kin1 
 
 
Mutations 
Note 
Mutations have not been detected. 
Implicated in 
Hepatocellular carcinogenesis 
Oncogenesis 
RT-PCR anaysis detected upregulated expression in 
nearly all clinical hepatocellular carcinoma cells in 
which nuclear accumulation of b-catenin was observed. 
Up-regulation and overexpression of 
MARK4 has been described in glial tumors and 
glioblastoma cell lines 
Oncogenesis 
MARK4 gene activation (enhanced expression and/or 
amplification) may result from intrachromo-somal 
duplication upon 19q rearrangements. 
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